Arcturus Therapeutics Inc - ARCT Net earnings per one share for the last twelve months

Arcturus Therapeutics profitability is based on the expansion of mRNA therapy within the rare disease segment. On the GURU.Markets platform, the annual EPS (TTM) change indicator demonstrates profit dynamics, where -25.30 reflects the latest value of the metric. Self-amplifying mRNA technology enhances the safety of liver treatment, while R&D development is fully funded through strategic licensing agreements with global pharma behemoths.
Arcturus Therapeutics - analytical breakdowns and key metrics (ARCT)

This metric measures the year-over-year dynamics of net income per share, reflecting the efficiency of business capitalization and the ability to generate income net of the cost of attracted resources. By analyzing the relative change chart of EPS YoY TTM, investors assess the monetization potential of the Arcturus Therapeutics (ARCT) R&D pipeline amid the market launch of mRNA products and the preparation of cystic fibrosis therapy.